World first innovation in cancer therapy at Great Ormond Street

The twinkling eyes and smile of Layla Richards shine out from many newspaper front pages today – and for a newsworthy reason. A world first treatment for her Acute Lymphoblastic Leukaemia was tried out by doctors at London’s Great Ormond Street Hospital. 

Screen Shot 2015-11-06 at 15.04.29

All of this went on without the Medical Innovation Bill or Access to Medical Treatments (Innovation) Bill.

Photo: Great Ormond Street Hospital

Lord Saatchi has consistently framed the need for his legislation with tales of denials of a potential cure, ‘wasted lives’, ‘cut and drilled’ on traumatic trajectories to death, as an uncaring and purely self-interested medical profession looks on.    

‘Current law in relation to medical negligence contributes to this failure. It defines medical negligence as deviation from standard procedure. But as innovation = deviation, then non-deviation = non- innovation.

The result is that all cancer deaths are wasted lives. The deaths, and their attendant tragedies, have not advanced scientific knowledge by one centimetre.


Because all the deceased have received is the standard procedure – the endless repetition of a failed experiment.’
–  Lord Maurice Saatchi

The rationale for the legislation was, apparently, and as has been written about extensively, to change the law and in turn encourage more doctors to innovate. 

The ‘current law obliges the doctor to follow the status quo, even though he/she knows it leads only to poor life quality followed by death.’

Screen Shot 2015-11-06 at 15.24.11

His claims have been repeated in briefing documents, in the press, at meetings, in the House of Lords and the House of Commons.

Screen Shot 2015-11-06 at 15.24.56

There is no need to change the law of negligence – as this already permits innovative practice. Nor is there any evidence to suggest any case in negligence has arisen due to responsible innovation in treatment, regardless of the outcome. Indeed there are many examples where the legal position is used expressly to favour an innovative approach. 

Those responding to the consultation and responding in an unwaveringly loud chorus against the proposals of any variation of the Bill have made it clear that if there are barriers to innovative treatment, the law of negligence is not the issue. Changing it will not help doctors, and will not help patients. Nor will it be inert. It is a deeply misguided attempt that is not based on evidence – ‘a solution in search of a problem and not  very sound solution at that’, surmised the National Assembly for Wales. The interim report of the Accelerated Access Review led by Sir Hugh Taylor makes no mention of the law of negligence or the fear of it as an obstruction to accessing innovative treatments. No legal, medical or research organisation supports this assertion either. The proposals would destroy the law that operates responsively and permissively to allow responsible innovation to happen today. 

It is time for Chris Heaton-Harris, Lord Saatchi and the Department of Health to recognise when it’s time to stop and- if truly concerned about patients and access to treatments-  assess any of the genuine barriers to access and support a change that would help, rather than harm doctors and patients – children like Layla in future. 


Photo: Great Ormond Street Hospital

Layla’s case

Read: Full account of Layla’s experience at GOSH

Baby Layla was diagnosed with ALL at 14 weeks. She received a bone marrow transplant and chemotherapy but they were not successful.  Shortly before her first birthday all normal treatments were exhausted, and her cancer was incurable. Her parents asked if anything else could be done.

A highly experimental therapy – tried only in mice- used TALEN gene editing technology to enzymatically deactivate genes in healthy donor T cells and precisely edit DNA to create ‘designer ‘cells targeted to the cancer that would withstand the necessary medication. After a 1ml infusion of 50m engineered cells over 10 minutes, a second bone marrow transplant 2 months later and now just 3 months down the line, baby Layla has a restored immune response and has been declared ‘cancer free’.   This is the first time- ever- that human cells engineered using this technology have been given back to a patient. The first trial of gene editing therapy was published last year, where an approach using a different DNA editing enzyme was used for HIV. 

Layla’s case will require very close follow-up and monitoring to ensure that the therapy is as effective as it appears to be, and a trial is planned for the approach next year. 

As Professor Waseem Qasim said: “We have only used this treatment on one very strong little girl and we have to be cautious about claiming this will be suitable for all children. But this is a landmark in the use of new gene engineering technology and the effects on this child have been staggering. If replicated, it could represent a huge step forward in treating leukaemia and other cancers.”

Here’s to Layla and her family – fantastic and all the very best!

I’ve been somewhat confused, says MP

Friday morning saw the second reading of the Access to Medical Treatments (Innovation) Bill – the latest incarnation of the Saatchi Bill – take place in the House of Commons.

Now, the list of those opposing the latest rehash of the Saatchi theme includes the Medical Royal Colleges, the BMA, the Association of Medical Research Charities and its constituent members such as Cancer Research UK, and many more. This was pointed out clearly and indefatigably. 

Dr Sarah Wollaston (Totnes) (Con): As with any book, we should not judge a Bill by its cover. All Members want to improve access to innovative medical treatments, but I sincerely believe that the Bill is not the right way forward. My hon. Friend the Member for Daventry (Chris Heaton-Harris) referred to a number of organisations, implying that they are in favour of the Bill, but he knows that the overwhelming majority of research and charitable organisations are ranged against it. It is opposed by the Association of Medical Research Charities, whose membership reads like an “A to Z” of expertise, including bodies such as Cancer Research UK, the Wellcome Trust—the list is very long, so I will not detain the House by reading it out. The Academy of Medical Sciences opposes the Bill, as does the Academy of Medical Royal Colleges, including all those he quoted in his speech.

The General Medical Council, the British Medical Association and the Patients Association oppose the Bill, and I direct my hon. Friend to their article in The Guardian. Action against Medical Accidents, and even the Association of the British Pharmaceutical Industry, oppose the Bill because of its unintended consequences. Legal experts, including Sir Robert Francis, firmly oppose the Bill. All those organisations oppose the Bill because it is unnecessary, it is unworkable, it would unravel important patient protections and, most importantly, it would have unintended and dangerous consequences for research.

I pay tribute to all the Bill’s sponsors and absolutely understand that they are motivated by very good intentions. I would love to sit down and work with them on how we genuinely improve access to innovative treatments. I hope they understand that I oppose the Bill because I sincerely believe that it is the wrong way forward.

Both Dr Wollaston and Labour Shadow Secretary of State for Health Heidi Alexander spoke with real and carefully applied insight to explain why there’s such concern about the baseless and ‘irresponsible’ proposals. 


Unfortunately, with only 51 MPs voting – despite the unwavering censure toward the latest version from expert medical organisations, research and patient safety charities –  it passed its second reading at 32 votes to 19. 

Mr Heaton-Harris  set about spinning support for the premise behind the Bill – despite his quoted organisations having reiterated their “unequivocal opposition” in new briefing notes. 

Dr Wollaston: My hon. Friend has quoted a number of organisations. Does he accept that all those organisations oppose the Bill? He needs to make that explicit to the House. It is not fair to quote the Royal College of Surgeons, for example, without making it clear that it has explicitly opposed this Bill.

This was nothing compared to the great lashings of nonsense brought forth by Philip Davies MP,  who selectively quoted snippets of consultation responses predating April 2014, out of context, defended by announcing “I am perfectly happy for people to put their own gloss on what others are saying” – when it was pointed out that others aren’t even saying anything like that, Davies continued to derail proceedings, talk in circles, and throw in half sentences, historic quotations, and confabulatory haze for over an hour.

Screen Shot 2015-10-16 at 19.56.18

Screen ShotScreen Shot 2

Seems he was at his filibustering best – most likely because of the next slot.

Screen Shot 2015-10-19 at 13.52.21

The Homes (Fitness for Human Habitation) Bill was an inconvenience to him that he succeeded in talking out.


Next up David Nuttall MP who managed to speak for many minutes without pausing to let in fact, and George Freeman MP- setting out the government’s position- conflating, again,the Early Access to Medicines Scheme with the Saatchi monster, and fudging plentifully.  Both denied that it would affect the law of negligence; so too did Chris Heaton-Harris MP. This was very interesting, seeing as its operative effect is to change the law of negligence.

Nuttall demonstrated how the Saatchi defence to negligent decisions operates:

‘I have to admit at the outset that an impressive array of bodies have lined up either in outright opposition to the Bill or with at least some reservations about it. When I was considering the evidence, I had to take that into account. I had to decide whether in the light of that evidence I should simply go with the flow and decide that if all those people said that it is a bad thing, it must be a bad thing, or whether I should think about the other side of the coin. I did that, and on balance, I came down on the side of what I like to think of as my constituents’ view. I believe that the Bill has the potential to improve the lives of my constituents if they are struck down by a rare disease that means that they require innovative medical treatment.’

Both Nuttall and Freeman mentioned litigation costs – but omitted that the known figure for litigation relating to innovation is … £0.

Dr Wollaston: How much of the litigation cost is related to complaints about innovative treatments?

George Freeman: Most of the cases are a result of other contexts – as my hon. Friend will know, obstetrics is a big part of that – rather than innovation. I am happy to write to her with the actual figure as I do not have it to hand…

All other pertinent questions were similarly obfuscated around.

Screen Shot 2015-10-19 at 14.38.14


Staggeringly the Access to Medical Treatments (Innovation) Bill edition of the Saatchi Bill was voted through to committee stage in the House of Commons, and while claiming it’s been ‘handed over’ to Heaton-Harris, Lord Saatchi’s Medical Innovation Bill remains in the House of Lords- alongside his motion to suspend SO46. 


Professor José Miola on the nonsense: ‘It’s like déjà vu all over again…’

What can be done?  Despair, despair some more – then contact your MP  ‘Call to action!’

Short shrift for Saatchi spin-off

We’ve been here beforeand, remarkably, here we are again. The weight of opposition to the Access to Medical Treatments (Innovation) Bill leaves no room for misunderstanding ahead of the second reading in the Commons.  

Screen Shot 2015-10-15 at 00.11.51

Screen Shot 2015-10-15 at 21.54.34

The British Medical Association, Patients Association, AvMA, Royal College of Surgeons, Royal College of Surgeons Edinburgh, Royal College of Paediatrics and Child Health, the Academy of Medical Royal Colleges and now the Association of Medical Research Charities and Medical Research Council are the latest to make their positions absolutely clear on the Bill, due its second reading in the House of Commons 16th October.

Screen Shot 2015-10-15 at 10.25.57

Screen Shot 2015-10-14 at 10.26.50

  • The Royal College of Surgeons  ‘unequivocally oppose’ the Bill. It is unnecessary with no evidence that any part of it is required. It misunderstands the doctor-patient relationship and could provide justification for unethical treatment. 

  • The RCPCH could not present a clearer warning of the ‘sinister piece of draft legislation’ lurking ‘which, if passed, will have detrimental effects on the wellbeing of children’.       ‘The Bill places patients – in particular infants, children and young people – at grave risk’, writes President Professor Modi.     The Bill will encourage irresponsible experimentation.  Families, already at heightened susceptibility…will be prey to at worst quackery and at best to the possibly strongly held but inadequately justified convictions of medical practitioners who do not know how, or do not wish, to test treatments objectively.’          ‘What’s more, the Bill’s stated purpose of enabling practitioners to employ innovative treatments without fear of litigation is completely unfounded.’    The Bill ‘will set back’ progress in bringing innovation into the care of sick children through clinical research, ‘legal and public confusion’ will ensue, efforts to improve understanding will suffer and support for research to improve the care of children will be at risk.’
  • The AMRC, representing 137 charities, and its members engaged in talks with Mr Heaton-Harris MP and communicated their concerns about the proposed draft. The organisation has now issued a formal briefing against the Access to Medical Treatments (Innovation) Bill, urging MPs to oppose the Bill as it is unnecessary and may adversely impact on patients and medical research.  Key members united as signatories to this briefing include Cancer Research UK, British Heart Foundation, MND Association, cancer charity Bloodies, the Academy of Medical Sciences, Alzheimer’s Research UK, Anthony Nolan, Arthritis Research UK, Ataxia UK, GI and liver disease charity CORE, The Encephalitis Society, The Brain Tumour Charity, Parkinson’s UK, Prostate Cancer UK, the Wellcome Trust, the British Pain Society, the Society for Endocrinology, British Orthopaedic Association, Autistica, Fight for Sight, Tuberous Sclerosis Association, Pelican Cancer Foundation, Pharmacy Research UK, and Genetic Alliance UK. 
  • The AoMRC , the representative body for the 16 Medical Royal Colleges, express ‘real concerns that the Bill will have unintended adverse consequences’, that it is ‘based on a false assumption’ with a ‘ false and potentially dangerous’ distinction between innovation and research.
  • The BMA firmly restate their position that the Bill is ‘unnecessary’, ‘counterproductive and…not based on any felt need from the medical profession.’  Screen Shot 2015-10-15 at 10.45.02They are clear that such ‘legislative proposals add nothing of value to the current law – rather, they increase bureaucracy and could create confusion, which may have implications for patient safety’.  Strong concerns are also expressed regarding a database.  ‘There are no plans for the information and innovative treatments to be quality assessed or peer reviewed. The inclusion of events on a database may give the impression that they are approved or have been given some form of endorsement for use again. This may lead to the inappropriate use of a treatment. Further it is not clear what safeguards will be in place ensure that all patient data is anonymised.’
  • The Medical Research Council ‘believe this Bill does not tackle the real barriers to adoption of medical innovation that need to be addressed, and may lead to unintended consequences’.
  • Patient safety and justice charity AvMA state that the Bill is ‘fraught with unintended and dangerous consequences’. It ‘would threaten patient safety’, fails to address anything that would benefit doctors or patients, and ‘as well as being based on a false premise, the Bill would actually make it harder to provide innovative treatment by creating a confusing, bureaucratic set of rules set in law’.
  • Conservative MP, GP and Health Select Committee Chair Dr Sarah Wollaston has spoken out to say that the rehash of what she previously termed the ‘Medical Anecdote Bill’ is still half-baked and dangerously rewarmed – ‘hopefully MPs will listen to all the serious concerns’. 
  • While academics note that it ‘does not help patients at all’.

The endless repetition of a failed experiment

Lord Saatchi’s Medical Innovation Bill and the new ‘Access to Medical Treatments (Innovation) Bill’, due for its second reading in the House of Commons on Friday 16th October, are cut from the same cloth – and it’s no Ede & Ravenscroft. Indeed, the Access to Medical Treatments (Innovation) Bill shares a similarly alluring [and similarly misleading] title –  and contains the same wording, the same premise and the same risks and problems as Saatchi’s originals.

Saatchi’s Medical Innovation Bill, version 7 or so, was not given extra special preferential deal time in the last parliament – if you’ll believe the Telegraph, it was “killed off” and Nick Clegg has “the blood of cancer patients on his hands” (having inspected I can confirm his hands are warm, well perfused, no Osler nodes, splinter haemorrhaging or blood of millions) – but, the Bill declared dead, deader than dead and gone, made a rather sprightly reappearance as soon as possible under the new parliament.   Now back in the House of Lords, Lord Saatchi put forward a motion to suspend SO46 which, if agreed, would permit his creation to pass through any number of stages on the same day.

Meanwhile, Saatchi endorsed a then-unannounced, entirely unwritten, conservative MP’s Private Members Bill as a new incarnation of his Medical Innovation Bill, carrying forward the Saatchi Bill to the Commons.  I get the impression that Chris Heaton-Harris is probably a nice guy who has some good ideas and probably has reasonable hands- indeed he wasn’t wholly sold on Saatchi’s plan himself – but whatever has pressed him into using his PMB ballot win on his/Saatchi’s new  ‘Access to Medical Treatments (Innovation) Bill’ – recently published – must be worth his while.

Now the really perplexing part. I mean, sure, it was perplexing to begin with – Lord Saatchi’s assertions in the House of Lords, articles in the Bill’s ‘media partner’ the Telegraph, google hangouts and briefing documents, included the following:

‘Current law requires that patients receive only standard procedure – the endless repetition of a failed experiment.’

‘In this way, the current law is a barrier to progress in curing cancer. It defines medical negligence as deviation from standard procedure. In other words, any deviation from standard procedure by a doctor could currently result in a verdict of guilt for medical negligence. However, as innovation is deviation, non-deviation is non-innovation.’


“The sentence of this Court is that you be taken from hence to the place of execution and that each of you there will be hanged by the neck until you be dead. And may Almighty God have mercy on your souls”

‘….much the same can be heard in every cancer ward in every NHS hospital every hour of every day

… those condemned by cancer suffer a worse fate than the worst mass murderer.

…While they await execution, they are tortured. For them, hair loss is the good news. Less good news is that their treatment regime—the drugs and the cycles of their administration, and the surgical procedures—are often 40 years old. They create the same symptoms as the disease: nausea, diarrhoea, vomiting and fatigue. A beautiful woman’s legs turn into elephant’s legs; her arms begin to make a heroin addict’s arms look attractive; and her bosoms turn into raisins’

‘The self-interest of medical practitioners…means that innovation (i.e. deviation) is a form of self-harm’

and so on, and on and on.

Er – right. Well, no; wrong. It is simply wrong. So wrong, that it’s hard to believe this can be serious.

Saatchi’s Medical Innovation Bill was met with widespread criticism from expert academics in law, medicine, medical defence and doctors’ representative organisations,  the regulator, the Royal Colleges, patient safety charities, medical research charities, clinicians, the National Assembly for Wales, and the likes of Sir Robert Francis QC and Sir Ian Kennedy QC, all of whom restated the correct law and emphasised the serious dangers and problems, and entirely flawed premise. The Department of Health consultation responses, withheld for some time, also revealed that just 10% would support it as it was.


‘The number of attempts at this Bill suggest it is not the right answer 

Each time objection has been raised to the Bill and its contents a different version is forthcoming.’

‘The difficulties that have caused so many drafts to be produced suggest that if there is to be legislation a more considered and less rushed approach is called for if we are to be satisfied that the patients who are intended to be benefit from this Bill, and patients generally, are not exposed to increased danger and risk.’

Medical Innovation Bill – Comments of Sir Robert Francis QC 23 June 2014


So, despite its intense polishing and spin, no-one with insight can possibly support it. There is no evidence to support its existence.  It does not stand up to scrutiny. 

Yet the situation today is this:

Chris Heaton-Harris MP has taken the Bill forward in the House of Commons – replicating the harmful bits, and adding some more.  


First published in September, the draft being taken forward on Friday has been finalised and published this week, along with ‘explanatory’ notes.

MPs are being presented with a whole brochure of masterful spin.

Sensing opposition rumbling, and the fact there’s no evidence in its favour, the medical innovation bill team have emailed asking for ‘stories’.. (‘cos that’s what sells stuff)

Screen Shot 2015-10-14 at 19.47.45


This would all have a bit of comedic value for a 10 minute exaggerated sketch.  But the mild bemusement at the return of this spectacle makes way for a grim disquiet.  The serious threat to patient safety, the woeful misapplication of the law, the distortion, confusion and hurdles for doctors, and the absolute refusal to acknowledge any real barriers to innovation – aren’t funny at all. 

Stop the Saatchi Bill Alliance would like as many people as possible to contact their MP before Friday, to stand up to this obvious abuse of process and prevent its disastrous consequences.

Screen Shot 2015-10-14 at 20.53.41

Stop the Bill now! was the plea from the Royal College of Paediatrics and Child Health, who note the ‘sinister’  and ‘disastrous’ Access to Medical Treatments (Innovation) Bill would place patients at grave risk; the Royal College of Surgeons has said it risks harming vulnerable patients and unequivocally opposes the Bill; RCSEd have told MPs it is unnecessary, dangerous and offers no practical assistance for responsible doctors -and  the Medical Royal Colleges have made their opposition clear. Again, the BMA have warned it is an unnecessary and nevertheless crude tool, that is counterproductive and would have implications for patient safety, and AvMA, charity for patient safety and justice, have expressed deep concern at the proposed, unnecessary, legislation- fraught with unintended and dangerous consequences.

See:  Stop the Saatchi Bill Alliance – Call to action!

Double, Double Toil and Trouble

The leaves are turning rusty brown, the weather turning crisper.  John Lewis are selling ghostly tinsel for Halloween. But something rather more scary is on the horizon.

Lord Saatchi’s Medical Innovation Bill reappeared after its demise in the last parliament. The legislative zombie crept back to the Lords and a motion was scheduled for it to be fast-tracked.  In the meantime, Lord Saatchi heralded Chris Heaton-Harris MP’s private members ballot win as the next carrier of the Bill’s baton before Mr Heaton-Harris admitted this himself.   It is now very clear that Saatchi was correct.

Screen Shot 2015-09-16 at 13.23.38

This next Saatchi Bill, be it Saatchi (No.9 3/4), Mambo (No.5), was ‘won’ by Chris Heaton Harris MP when his name came up in the draw and the Saatchi lobby were in. It has just been published in draft form and it would appear that Mr Heaton-Harris sat back and thought of England while it was being drafted. Nurtured through the medium of cut and paste by the Department of Health, it is an almost identical replica of the much-criticised Saatchi horror, with some clangers thrown in to spin it in a better light without any substantive change to the concerning aspects of the original(s). 

As Sir Robert Francis QC observed in his comments over a year ago on Saatchi’s Bill; 

‘The evidence relied on by Lord Saatchi…does not provide the convincing support claimed. The difficulties that have caused so many drafts to be produced suggest that if there is to be legislation a more considered and less rushed approach is called for if we are to be satisfied that the patients who are intended to be benefit from this Bill, and patients generally, are not exposed to increased danger and risk.’

‘The number of attempts at this Bill suggest it is not the right answer… the deficiencies all versions show indicate that it would be quite wrong to rush legislation through… Considered scrutiny is required … calm assessment of the evidence of what are the real problems in practice.’

Despite evidence, reports, and meetings with concerned parties and expert organisations at the Heaton-Harris fingertips it seems that none of what made Saatchi’s originals awful has been removed. Indeed it is a reproduction of the original, with a database.  Everything that made the originals terrible still stands. And despite the alluring title of Access to Medical Treatments (Innovation) Bill, it contains nothing at all about access to medical treatments or innovation for patients, and nothing at all to address such access issues for their doctors.  

Indeed what it does is: preserve a complete defence to negligence for doctors who are actually so bad, so irresponsible, so irrational, so illogical in their treatment decisions, that they would be classed as negligent.  These are the only doctors it helps.  Not the majority of doctors, but the very minority that should not be protected by the law.

It does not preserve the common law tests of Bolam/Bolitho but jumbles concepts into nonsense.  It would prevent people who are injured from obtaining compensation to help them live or help them pay for the carers they need after sustaining injuries from negligent treatment decisions – all this despite there being no evidence that innovative treatment forms the basis of such claims.  It does nothing to ensure a patient is in the driving seat and improve communication and informed decision making, and nothing to address any barriers to accessing treatments that may actually help patients.

It applies squarely to those decisions which no other doctor would support or which are so indefensibly irrational that they are negligent.

It does not limit the scope of the Bill in the patients it can apply to or in what is classed as innovation, and thus does not limit the scope of this defence. Homeopathic remedies for childhood leukaemia would be a-okay under this defence if the process was followed when deciding to give a dying child a homeopathic tincture, rather than chemotherapy or another proven treatment and rather than include them in a global trial for a promising drug for their precise diagnosis. A wildly experimental drug from a pharmaceutical company the prescriber is a shareholder in, one that shortens lives and removes all quality of life for those who take it and inflicts a terminal suffering, sold as hope in a capsule- well, yeah that wouldn’t be a problem either. 

It adds a completely separate concept of a database – ignoring the fact that such results are meaningless without clear methodology in data collection, reporting and conduct and patient selection, ignoring swathes of data security concerns, confidentiality factors, EU regulatory and even insurance issues; all the while missing the entire point of such initiatives as the AllTrials campaign which are very worthy of support. Nevertheless any such database could operate without the firmly refuted Saatchi Bill proforma defence for negligence.  The ‘that sounds good let’s say that’ hooks added for selling points are completely meaningless, confused, soundbites that demonstrate a lack of understanding and substance. Patients deserve better care than that. 

For excellent analysis please see:

Chris Heaton-Harris Resurrects Lord Saatchi’s Zombie Quacks’ Charter

Learned Friend: Access to Medical Treatments (Innovation) Bill 2015


this paper: Bye Bye Bolitho? The Curious Case of the Medical Innovation Bill


More Trick than Treat

cauldronLord Saatchi’s PMB has tortuously rattled around despite loud criticism from all key experts, medical organisations, research and patient charities. Unusually, a No.2 bill procedure was used to introduce it into the Lords and the Commons simultaneously in 2012. Much criticism led to its withdrawal from the Commons and a second draft, the Medical Innovation (No.2) Bill, in the Lords. A Department of Health consultations as issued on the second version of this, and this consultation closed in April 2014. Before the responses were published, a new, third draft had been written and announced as improved and an answer to all criticism. Its first reading in the Lords, a formality, was on 5 June 2014 and its second took place on 27 June 2014. It was amended again following the second reading, and it entered committee stage as its fourth version, with 39 amendments tabled. It was amended again prior to Report stage, and again thereafter, and again (v7, mark 2).   Once to the Commons Saatchi thought he’d get extra time in the last parliament to push it through and into law before the general election – despite legislative consent being unanimously rejected by a country. Indeed, if no MP objected and no amendments were tabled it could have been rushed through to Royal Assent in a day. Sarah Wollaston and Julian Huppert arranged a rota so that one of them, at least, would be around to object. When debating time and special deals were hanging in the balance the coalition government parted ways when someone said hang on, all the stakeholders say this is dangerous – let’s not do this.  

Despite the ongoing opposition from across the board: medical organisations, patient charities and groups, research charities, academics, legal and patient safety experts, Lord Saatchi reintroduced his Bill in 2015/16 in the configuration it had left the Lords – and a motion to set aside SO46 (Standing Order 46 of the House of Lords, a rule that no two stages of a Bill shall be taken in one day) was scheduled which would allow a fast tracked passing back to the Commons and even passing its stages in one day, averting the proper scrutiny of the chambers.   The motion to set aside SO46 is still scheduled for November and would allow the original Medical Innovation (No.2) Bill to pass. But Lord Saatchi has now confirmed that Chris Heaton-Harris’s private members bill IS the Medical Innovation Bill handed over, and thus given more time to run. 

The second reading of the Access to Medical Treatments (Innovation) Bill is now scheduled for 16 October 2015 in the House of Commons.


Blink and it’s back, again, twice

In a fascinating display of parliamentary quick change tango, Lord Saatchi’s creation has hotfooted not only back to the Lords to be read a second time in July (with the hopes of subverting usual procedure and fast-tracking straight to the lower house for its completion- with a time limit of one year from its reappearance) but, according to the Bill’s website, it is now replicated in the PMB proposed by MP Chris Heaton-Harris in the Commons.

Of course, if this is the case then it’s gone from a, relatively, restrained misrepresenting of benefit by using the word ‘innovation’ rather than ‘experimentation’; to a wholesale misrepresentation of content. The original never contained anything that would have enabled access to treatment,at all, despite the heavy lines spun to encourage loud, urgent, understandable, support.  One suspects Lord Saatchi’s new bill will be the same when it suits him to dupe supporters into believing it’s had the ok-go from the Lords; and will be an entirely new and fresh venture when the hideous problems and wall of opposition, from doctors’ representatives, patient charities, research groups and patient safety experts, to the original attempts are pointed out.    Nobody’s quite sure whether the Bill site has told the truth or not because the Bill probably hasn’t been written yet, despite having its first reading yesterday. Nor can anyone know how many willing helpers put their names in for the PMB ballot to run it for Saatchi; brownie points all round, right?
And what dazzling speed – Britain’s got talent for something, anyway, just apparently not appropriate, considered, transparent health policy or legislative drafting.
From the website:
Screen Shot 2015-06-25 at 19.33.38Screen Shot 2015-06-25 at 19.33.58
With a typically overt disregard for quality of life or respect for human worth, the mass guinea pig market was announced in the Telegraph as well, will they be this Bill’s media partner too?
On the plus side, Tredinnick’s cleared off temporarily for his gig at Glastonbury.

Anticoagulation, powdered owl & an outlier on the spectrum of reason

A GP with decades of experience in practice and medical education, Dr Wollaston became an MP in 2010 after an open primary in Totnes. Her invaluable experience and insight on national and local issues of importance as well as her specialist expertise made her the ideal choice to inform the Westminster vacuum.

She was soon appointed to the Health Select Committee, a cross-party committee to hold the government and health bodies to account and make policy recommendations. In 2014 she was elected Chair. She did a fantastic job in the role and it would be a terrible disservice to health policy, the committee and the government’s credibility if she were not Chair again. Very few are as qualified and appropriate for the role and,  felt keenly with the absence of such MPs as Julian Huppert on this occasion, we need to maximise the insightful few that we have. She’s also a rather great role model.

Her challenger for the role is David Tredinnick.

Why is that news? Well it’s perhaps not that newsworthy I guess, and that’s what’s scary. 

David Tredinnick’s appointment to the Health Select Committee itself was really quite shocking, but that was way back in 2010. Though inapposite, add in the company of other desperately unqualified persons such as Nadine Dorries and it’s no longer a surprise.   

Tredinnick, MP is so out there he’s ‘a hallucinogenic substance in his own right’.  He is a big supporter of his own variant of astrology, not only claiming for personal development courses, but once claiming expenses from taxpayers for £755.33 of ‘computer software and consultancy to investigate whether astrology can be linked to alternative medicine.’

In the House of Commons he has stated emphatically that blood does not clot on a full moon, and surgeons won’t operate on full moons. Indeed his fear of the moon has been raised on a number of occasions.   He launched a tirade of EDMs at the indignance of people who knew what they were talking about to talk about stuff, like homeopathy; and relied upon so-completely-unambiguously-discredited studies to support his claims, even those which claimed to cure cancer and where authors asked to be removed from papers. 

Like Australia have concluded, our Science and Technology Committee found homeopathy useless. David Tredinnick then joined the Committee.  

He still believes astrology should be used more often in healthcare in the UK.  Recently in 2015 he reiterated the virtues of astrology as “a useful diagnostic tool enabling us to see strengths and weaknesses via the birth chart” and proclaimed that astrology and complementary medicine “would help take the huge pressure off doctors”. So much for Francis and safe staffing. Perhaps NICE have already a-okayed this as it’s clearly cheaper to replace legitimate health policy with the nuttier side of woomongery’. 

‘How to handle the ongoing issue of having this bizarre, deeply wrongheaded man in a position of influence over matters that demand evidence-based decision making?’ asked Adam Rutherford, 5 years ago.   The indulgence of his personal interest in astrology to the detriment and exclusion of real matters for his constituents and for the health of the nation has not gone unnoticed in parliament either. 

But now this man, who Professor Brian Cox politely termed ‘an outlier on the spectrum of reason’  not only wants to be on it, he has been nominated to chair the Health Select Committee. 

Beating cancer with astrology

Beating cancer with astrology

Almost impossible to parody it’s not actually funny.

These are not the affable, eccentricities of your distant uncle or your old headmaster. This is not harmless.

Championing discredited studies as evidence in parliament, including for cancer treatment, is deeply contemptible. Steering health policy in this way is like crashing it into the dover cliffs. It’s not “the awesome power of the moon” flinging it there – it’s Westminster sinking itself, and the rest of us in the process. 

More from Professor Cox here.